BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 22109108)

  • 21. The role of DNA hypermethylation in human neoplasia.
    Toyota M; Issa JP
    Electrophoresis; 2000 Jan; 21(2):329-33. PubMed ID: 10675010
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ependymoma-like tumor with mesenchymal differentiation harboring C11orf95-NCOA1/2 or -RELA fusion: A hitherto unclassified tumor related to ependymoma.
    Tomomasa R; Arai Y; Kawabata-Iwakawa R; Fukuoka K; Nakano Y; Hama N; Nakata S; Suzuki N; Ishi Y; Tanaka S; Takahashi JA; Yuba Y; Shiota M; Natsume A; Kurimoto M; Shiba Y; Aoki M; Nabeshima K; Enomoto T; Inoue T; Fujimura J; Kondo A; Yao T; Okura N; Hirose T; Sasaki A; Nishiyama M; Ichimura K; Shibata T; Hirato J; Yokoo H; Nobusawa S
    Brain Pathol; 2021 May; 31(3):e12943. PubMed ID: 33576087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genome-wide methylation analysis identifies a core set of hypermethylated genes in CIMP-H colorectal cancer.
    McInnes T; Zou D; Rao DS; Munro FM; Phillips VL; McCall JL; Black MA; Reeve AE; Guilford PJ
    BMC Cancer; 2017 Mar; 17(1):228. PubMed ID: 28351398
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aberrantly hypermethylated tumor suppressor genes were identified in oral squamous cell carcinoma (OSCC).
    Kim SY; Han YK; Song JM; Lee CH; Kang K; Yi JM; Park HR
    Clin Epigenetics; 2019 Aug; 11(1):116. PubMed ID: 31405379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Specific chromosomal imbalances as detected by array CGH in ependymomas in association with tumor location, histological subtype and grade.
    Rousseau A; Idbaih A; Ducray F; Crinière E; Fèvre-Montange M; Jouvet A; Delattre JY
    J Neurooncol; 2010 May; 97(3):353-64. PubMed ID: 19865800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. C11orf95-RELA fusion present in a primary supratentorial ependymoma and recurrent sarcoma.
    Cachia D; Wani K; Penas-Prado M; Olar A; McCutcheon IE; Benjamin RS; Armstrong TS; Gilbert MR; Aldape KD
    Brain Tumor Pathol; 2015 Apr; 32(2):105-11. PubMed ID: 25388523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors.
    Ellison DW; Aldape KD; Capper D; Fouladi M; Gilbert MR; Gilbertson RJ; Hawkins C; Merchant TE; Pajtler K; Venneti S; Louis DN
    Brain Pathol; 2020 Sep; 30(5):863-866. PubMed ID: 32502305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MRI Phenotype of RELA-fused Pediatric Supratentorial Ependymoma.
    Nowak J; Jünger ST; Huflage H; Seidel C; Hohm A; Vandergrift LA; von Hoff K; Rutkowski S; Pietsch T; Warmuth-Metz M
    Clin Neuroradiol; 2019 Dec; 29(4):595-604. PubMed ID: 30027327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma.
    Merchant TE; Bendel AE; Sabin ND; Burger PC; Shaw DW; Chang E; Wu S; Zhou T; Eisenstat DD; Foreman NK; Fuller CE; Anderson ET; Hukin J; Lau CC; Pollack IF; Laningham FH; Lustig RH; Armstrong FD; Handler MH; Williams-Hughes C; Kessel S; Kocak M; Ellison DW; Ramaswamy V
    J Clin Oncol; 2019 Apr; 37(12):974-983. PubMed ID: 30811284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survival.
    Lukashova-v Zangen I; Kneitz S; Monoranu CM; Rutkowski S; Hinkes B; Vince GH; Huang B; Roggendorf W
    Acta Neuropathol; 2007 Mar; 113(3):325-37. PubMed ID: 17265049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic inactivation of MCJ (DNAJD1) in malignant paediatric brain tumours.
    Lindsey JC; Lusher ME; Strathdee G; Brown R; Gilbertson RJ; Bailey S; Ellison DW; Clifford SC
    Int J Cancer; 2006 Jan; 118(2):346-52. PubMed ID: 16049974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.
    Feng W; Marquez RT; Lu Z; Liu J; Lu KH; Issa JP; Fishman DM; Yu Y; Bast RC
    Cancer; 2008 Apr; 112(7):1489-502. PubMed ID: 18286529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas.
    Pajtler KW; Wen J; Sill M; Lin T; Orisme W; Tang B; Hübner JM; Ramaswamy V; Jia S; Dalton JD; Haupfear K; Rogers HA; Punchihewa C; Lee R; Easton J; Wu G; Ritzmann TA; Chapman R; Chavez L; Boop FA; Klimo P; Sabin ND; Ogg R; Mack SC; Freibaum BD; Kim HJ; Witt H; Jones DTW; Vo B; Gajjar A; Pounds S; Onar-Thomas A; Roussel MF; Zhang J; Taylor JP; Merchant TE; Grundy R; Tatevossian RG; Taylor MD; Pfister SM; Korshunov A; Kool M; Ellison DW
    Acta Neuropathol; 2018 Aug; 136(2):211-226. PubMed ID: 29909548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment.
    Witt H; Gramatzki D; Hentschel B; Pajtler KW; Felsberg J; Schackert G; Löffler M; Capper D; Sahm F; Sill M; von Deimling A; Kool M; Herrlinger U; Westphal M; Pietsch T; Reifenberger G; Pfister SM; Tonn JC; Weller M;
    Neuro Oncol; 2018 Nov; 20(12):1616-1624. PubMed ID: 30053291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma.
    Thomas C; Thierfelder F; Träger M; Soschinski P; Müther M; Edelmann D; Förster A; Geiler C; Kim HY; Filipski K; Harter PN; Schittenhelm J; Eckert F; Ntoulias G; May SA; Stummer W; Onken J; Vajkoczy P; Schüller U; Heppner FL; Capper D; Koch A; Kaul D; Paulus W; Hasselblatt M; Schweizer L
    Acta Neuropathol; 2021 Jun; 141(6):959-970. PubMed ID: 33755803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The transcription factor evi-1 is overexpressed, promotes proliferation, and is prognostically unfavorable in infratentorial ependymomas.
    Koos B; Bender S; Witt H; Mertsch S; Felsberg J; Beschorner R; Korshunov A; Riesmeier B; Pfister S; Paulus W; Hasselblatt M
    Clin Cancer Res; 2011 Jun; 17(11):3631-7. PubMed ID: 21493867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of key methylation differentially expressed genes in posterior fossa ependymoma based on epigenomic and transcriptome analysis.
    Wang G; Jia Y; Ye Y; Kang E; Chen H; Wang J; He X
    J Transl Med; 2021 Apr; 19(1):174. PubMed ID: 33902636
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of global 5-hydroxymethylcytosine in pediatric posterior fossa ependymoma.
    Wu T; Zhang ZW; Li S; Wang B; Yang Z; Li P; Zhang J; Tong WM; Li C; Zhao F; Niu Y; Liu P
    Clin Epigenetics; 2020 Jan; 12(1):19. PubMed ID: 31992357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
    Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
    Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aberrant CpG island methylation of multiple genes in ependymal tumors.
    Alonso ME; Bello MJ; Gonzalez-Gomez P; Arjona D; de Campos JM; Gutierrez M; Rey JA
    J Neurooncol; 2004; 67(1-2):159-65. PubMed ID: 15072463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.